資料簡(jiǎn)介
advimmuno2024年價(jià)格表
美國(guó)加利福尼亞州Advanced Immunochemical公司是一家全球g認(rèn)的免疫試劑供應(yīng)商,我們?cè)诙鄠€(gè)臨床領(lǐng)域提供產(chǎn)品,包括心臟標(biāo)志物、代謝綜合征(包括糖尿病)、傳染病和獸醫(yī)診斷。我們將免疫學(xué)原料、技術(shù)支持和 AssayNotes 相結(jié)合,為我們的客戶提供了推進(jìn)診斷檢測(cè)開發(fā)和進(jìn)一步臨床應(yīng)用的可靠手段。advimmuno為全球的科學(xué)家提供高質(zhì)量的產(chǎn)品,主要包括單克隆抗體、多克隆抗體、抗原、酶、激酶和純化蛋白。
特別告知:為保證產(chǎn)品質(zhì)量與良好性能,所以在購(gòu)買相應(yīng)產(chǎn)品的同時(shí)我司會(huì)收取一定量的運(yùn)輸費(fèi)用!!!本次報(bào)價(jià)有效時(shí)間為2024年1月10日---2024年12月14日。
貨號(hào) | 品名 | 規(guī)格 | 價(jià)格 | 品牌 | 貨期 | 價(jià)格來源 |
8-ADP-0.05mg | Adiponectin, human, native | 0.05mg | 22560 | advimmuno | 4-5周 | 上海起發(fā) |
8-ADP-0.1mg | Adiponectin, human, native | 0.1mg | 22560 | advimmuno | 4-5周 | 上海起發(fā) |
8-CA153 | CA15-3, standard grade | 250kiu | 39760 | advimmuno | 4-5周 | 上海起發(fā) |
8-CRP2-0.5mg | C-reactive protein (CRP), human, recombinant | 0.5mg | 6000 | advimmuno | 4-5周 | 上海起發(fā) |
8-CRP2-1mg | C-reactive protein (CRP), human, recombinant | 1mg | 4160 | advimmuno | 4-5周 | 上海起發(fā) |
8-CYC-0.05mg | Human cystatin C | 0.05mg | 12560 | advimmuno | 4-5周 | 上海起發(fā) |
8-CYC-0.1mg | Human cystatin C | 0.1mg | 19120 | advimmuno | 4-5周 | 上海起發(fā) |
8-CYC-rh | Recombinant human cystatin C | 0.1mg | 8800 | advimmuno | 4-5周 | 上海起發(fā) |
8-DD1-0.1mg | D-dimer Antigen | 0.1mg | 17440 | advimmuno | 4-5周 | 上海起發(fā) |
8-DD1-0.5mg | D-dimer Antigen | 0.5mg | 34720 | advimmuno | 4-5周 | 上海起發(fā) |
8-FABP-0.1mg | Fatty acid binding protein (FABP), human | 0.1mg | 13760 | advimmuno | 4-5周 | 上海起發(fā) |
8-FABP-0.5mg | Fatty acid binding protein (FABP), human | 0.5mg | 27440 | advimmuno | 4-5周 | 上海起發(fā) |
8-GproNP | Human recombinant proBNP, glycosylated | 0.05mg | 40400 | advimmuno | 4-5周 | 上海起發(fā) |
8-IGBPC-rh-0.05mg | Recombinant human Insulin-like growth factor binding protein 4, C-terminal fragment (CT-IGFBP- 4) | 0.05mg | 32960 | advimmuno | 4-5周 | 上海起發(fā) |
8-IGBPC-rh-0.1mg | Recombinant human Insulin-like growth factor binding protein 4, C-terminal fragment (CT-IGFBP- 4) | 0.1mg | 50080 | advimmuno | 4-5周 | 上海起發(fā) |
8-IGBPN-rh-0.05mg | Recombinant human Insulin-like growth factor binding protein 4, N-terminal fragment (NT-IGFBP- 4) | 0.05mg | 32960 | advimmuno | 4-5周 | 上海起發(fā) |
8-IGBPN-rh-0.1mg | Recombinant human Insulin-like growth factor binding protein 4, N-terminal fragment (NT-IGFBP- 4) | 0.1mg | 65840 | advimmuno | 4-5周 | 上海起發(fā) |
8-KIM-rh | Recombinant human kidney injury molecule (KIM-1), ectodomain | 0.05mg | 31040 | advimmuno | 4-5周 | 上海起發(fā) |
8-MYG-0.5mg | Myoglobin | 0.5mg | 16400 | advimmuno | 4-5周 | 上海起發(fā) |
8-MYG-1mg | Myoglobin | 1mg | 11440 | advimmuno | 4-5周 | 上海起發(fā) |
8-NSE-0.5mg | Neuron-specific enolase (NSE) | 0.5mg | 25200 | advimmuno | 4-5周 | 上海起發(fā) |
8-NTpB-rh-0.05mg | Human recombinant NT-proBNP (amino terminal human brain natriuretic peptide precursor) | 0.05mg | 20240 | advimmuno | 4-5周 | 上海起發(fā) |
8-NTpB-rh-0.1mg | Human recombinant NT-proBNP (amino terminal human brain natriuretic peptide precursor) | 0.1mg | 39360 | advimmuno | 4-5周 | 上海起發(fā) |
8-pB-rh-0.05mg | Human recombinant proBNP (human brain natriuretic peptide precursor) | 0.05mg | 21440 | advimmuno | 4-5周 | 上海起發(fā) |
8-pB-rh-0.1mg | Human recombinant proBNP (human brain natriuretic peptide precursor) | 0.1mg | 32640 | advimmuno | 4-5周 | 上海起發(fā) |
8-RBP4-c | Retinol-binding protein 4 (RBP4) from human plasma, complexed with prealbumin | 0.1mg | 8880 | advimmuno | 4-5周 | 上海起發(fā) |
8-RBP4-f | Retinol-binding protein 4 (RBP4) from human plasma, free form | 0.1mg | 7200 | advimmuno | 4-5周 | 上海起發(fā) |
8-S100ab-b-0.1mg | S-100 protein, ?? homodimer and ?? heterodimer, bovine | 0.1mg | 10800 | advimmuno | 4-5周 | 上海起發(fā) |
8-S100ab-b-0.5mg | S-100 protein, ?? homodimer and ?? heterodimer, bovine | 0.5mg | 21600 | advimmuno | 4-5周 | 上海起發(fā) |
8-S100ab-h-0.1mg | S-100 protein, ?? homodimer and ?? heterodimer, human | 0.1mg | 10800 | advimmuno | 4-5周 | 上海起發(fā) |
8-S100ab-h-0.5mg | S-100 protein, ?? homodimer and ?? heterodimer, human | 0.5mg | 21600 | advimmuno | 4-5周 | 上海起發(fā) |
8-S100bb-b-0.1mg | S-100 protein, ?? homodimer, bovine | 0.1mg | 23920 | advimmuno | 4-5周 | 上海起發(fā) |
8-S100bb-b-0.5mg | S-100 protein, ?? homodimer, bovine | 0.5mg | 47840 | advimmuno | 4-5周 | 上海起發(fā) |
8-S100bb-h-0.1mg | S-100 protein, ?? homodimer, human | 0.1mg | 23920 | advimmuno | 4-5周 | 上海起發(fā) |
8-S100bb-h-0.5mg | S-100 protein, ?? homodimer, human | 0.5mg | 47840 | advimmuno | 4-5周 | 上海起發(fā) |
8-TIc-h-0.1mg | Human cardiac troponin I (cTnI) | 0.1mg | 32720 | advimmuno | 4-5周 | 上海起發(fā) |
8-TIc-h-0.5mg | Human cardiac troponin I (cTnI) | 0.5mg | 65280 | advimmuno | 4-5周 | 上海起發(fā) |
8-TIC-rh-0.05mg | Recombinant human cardiac troponin I (cTnI) | 0.05mg | 16080 | advimmuno | 4-5周 | 上海起發(fā) |
8-TIC-rh-0.1mg | Recombinant human cardiac troponin I (cTnI) | 0.1mg | 24480 | advimmuno | 4-5周 | 上海起發(fā) |
8-TIs-h-0.1mg | Human skeletal muscle troponin I (skTnI) | 0.1mg | 20560 | advimmuno | 4-5周 | 上海起發(fā) |
8-TIs-h-0.5mg | Human skeletal muscle troponin I (skTnI) | 0.5mg | 41120 | advimmuno | 4-5周 | 上海起發(fā) |
8-TnC-h-0.1mg | Human troponin C (TnC) | 0.1mg | 20560 | advimmuno | 4-5周 | 上海起發(fā) |
8-TnC-h-0.5mg | Human troponin C (TnC) | 0.5mg | 41120 | advimmuno | 4-5周 | 上海起發(fā) |
8-TRs-0.1mg | Recombinant soluble transferrin receptor (sTfR) | 0.1mg | 12480 | advimmuno | 4-5周 | 上海起發(fā) |
8-TRs-0.5mg | Recombinant soluble transferrin receptor (sTfR) | 0.5mg | 19360 | advimmuno | 4-5周 | 上海起發(fā) |
9-IG5-h-0.5mg | Monosialoganglioside GM2, human | 0.5mg | 15600 | advimmuno | 4-5周 | 上海起發(fā) |
9-IG6-h-0.5mg | Disialoganglioside GD2, human | 0.5mg | 16000 | advimmuno | 4-5周 | 上海起發(fā) |
(*此為部分產(chǎn)品價(jià)格完整價(jià)格請(qǐng)下載文件)
關(guān)鍵詞:advimmuno、多克隆抗體、抗原、酶、純化蛋白
相關(guān)產(chǎn)品
免責(zé)聲明
- 凡本網(wǎng)注明“來源:化工儀器網(wǎng)”的所有作品,均為浙江興旺寶明通網(wǎng)絡(luò)有限公司-化工儀器網(wǎng)合法擁有版權(quán)或有權(quán)使用的作品,未經(jīng)本網(wǎng)授權(quán)不得轉(zhuǎn)載、摘編或利用其他方式使用上述作品。已經(jīng)本網(wǎng)授權(quán)使用作品的,應(yīng)在授權(quán)范圍內(nèi)使用,并注明“來源:化工儀器網(wǎng)”。違反上述聲明者,本網(wǎng)將追究其相關(guān)法律責(zé)任。
- 本網(wǎng)轉(zhuǎn)載并注明自其他來源(非化工儀器網(wǎng))的作品,目的在于傳遞更多信息,并不代表本網(wǎng)贊同其觀點(diǎn)和對(duì)其真實(shí)性負(fù)責(zé),不承擔(dān)此類作品侵權(quán)行為的直接責(zé)任及連帶責(zé)任。其他媒體、網(wǎng)站或個(gè)人從本網(wǎng)轉(zhuǎn)載時(shí),必須保留本網(wǎng)注明的作品第一來源,并自負(fù)版權(quán)等法律責(zé)任。
- 如涉及作品內(nèi)容、版權(quán)等問題,請(qǐng)?jiān)谧髌钒l(fā)表之日起一周內(nèi)與本網(wǎng)聯(lián)系,否則視為放棄相關(guān)權(quán)利。